Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP
Haiyan Ge,1,* Xuanqi Liu,1,* Wenchao Gu,2 Xiumin Feng,3,4 Fengying Zhang,5 Fengfeng Han,6 Yechang Qian,7 Xiaoyan Jin,8 Beilan Gao,9 Li Yu,10 Hong Bao,11 Min Zhou,12 Shengqing Li,13 Zhijun Jie,14 Jian Wang,15 Zhihong Chen,16 Jingqing Hang,5 Jingxi Zhang,3 Huili Zhu1 1Department of Res...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8a577d638cf445f1bc01de57d030c092 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8a577d638cf445f1bc01de57d030c092 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
chronic obstructive pulmonary disease (copd) exacerbation comorbidity risk score Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
chronic obstructive pulmonary disease (copd) exacerbation comorbidity risk score Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Ge H Liu X Gu W Feng X Zhang F Han F Qian Y Jin X Gao B Yu L Bao H Zhou M Li S Jie Z Wang J Chen Z Hang J Zhang J Zhu H Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| description |
Haiyan Ge,1,* Xuanqi Liu,1,* Wenchao Gu,2 Xiumin Feng,3,4 Fengying Zhang,5 Fengfeng Han,6 Yechang Qian,7 Xiaoyan Jin,8 Beilan Gao,9 Li Yu,10 Hong Bao,11 Min Zhou,12 Shengqing Li,13 Zhijun Jie,14 Jian Wang,15 Zhihong Chen,16 Jingqing Hang,5 Jingxi Zhang,3 Huili Zhu1 1Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Respiratory Medicine, Pudong New District People’s Hospital, Shanghai, People’s Republic of China; 3Department of Respiratory and Critical Care Medicine, Changhai Hospital Affiliated to Navy Military Medical University, Shanghai, People’s Republic of China; 4Department of Respiratory and Critical Care Medicine, Changji Branch of First Affiliated Hospital of Xinjiang Medical University, Xinjiang, People’s Republic of China; 5Department of Respiratory Medicine, Putuo District People’s Hospital, Shanghai, People’s Republic of China; 6Department of Respiratory Medicine, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 7Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, People’s Republic of China; 8Department of Respiratory Medicine, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 9Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of China; 10Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 11Department of Respiratory Medicine Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People’s Republic of China; 12Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 13Department of Respiratory and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 14Department of Respiratory Medicine, Shanghai Fifth’s Hospital, Fudan University, Shanghai, People’s Republic of China; 15Department of Respiratory Medicine, Shanghai Ninth’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 16Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huili Zhu Email zhuhuili001@126.comJingxi Zhang Email jingxizhang2000@126.comBackground: Chronic obstructive pulmonary disease (COPD) often coexists with multiple comorbidities which may have a significant impact on acute exacerbations of patients. At present, what kind of comorbidities affects acute exacerbations and how comorbidities lead to poor prognosis are still controversial. The purpose of our study is to determine the impact of comorbidities on COPD exacerbation and establish an acute exacerbation risk assessment system related to comorbidities.Methods: A total of 742 COPD patients participated in the Shanghai COPD Investigation on Comorbidity Program (SCICP, ChiCTR2000030911). Finally, the baseline information of 415 participants and one-year follow-up data were involved in the analysis. We collected hemogram indices, pulmonary function tests and acute exacerbation of COPD with regular medical follow-up. Q-type cluster analysis was used to determine the clusters of participants. Receiver operating characteristic (ROC) analysis was constructed to assess the ability of indicators in predicting acute exacerbations.Results: Almost 65% of the population we investigated had at least one comorbidity. The distribution and incidence of comorbidities differed between exacerbation group and non-exacerbation group. Three comorbidity clusters were identified: (1) respiratory, metabolic, immune and psychologic disease (non-severe cases); (2) cardiovascular and neoplastic disease (severe cases); (3) less comorbidity. Different sub-phenotypes of COPD patients showed significant distinction in health status. Anxiety (OR=5.936, P=0.001), angina (OR=10.155, P=0.025) and hypertension (OR=3.142, P=0.001) were found to be independent risk factors of exacerbation in a year. The novel risk score containing BODEx and four diseases showed great prognostic value of COPD exacerbation in developing sample.Conclusion: Our study detailed the major interaction between comorbidities and exacerbation in COPD. Noteworthily, a novel risk score using comprehensive index – BODEx – and comorbidity parameters can identify patients at high risk of acute exacerbation.Keywords: chronic obstructive pulmonary disease, exacerbation, comorbidity, risk score |
| format |
article |
| author |
Ge H Liu X Gu W Feng X Zhang F Han F Qian Y Jin X Gao B Yu L Bao H Zhou M Li S Jie Z Wang J Chen Z Hang J Zhang J Zhu H |
| author_facet |
Ge H Liu X Gu W Feng X Zhang F Han F Qian Y Jin X Gao B Yu L Bao H Zhou M Li S Jie Z Wang J Chen Z Hang J Zhang J Zhu H |
| author_sort |
Ge H |
| title |
Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| title_short |
Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| title_full |
Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| title_fullStr |
Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| title_full_unstemmed |
Distribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP |
| title_sort |
distribution of copd comorbidities and creation of acute exacerbation risk score: results from scicp |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/8a577d638cf445f1bc01de57d030c092 |
| work_keys_str_mv |
AT geh distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT liux distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT guw distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT fengx distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT zhangf distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT hanf distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT qiany distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT jinx distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT gaob distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT yul distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT baoh distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT zhoum distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT lis distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT jiez distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT wangj distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT chenz distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT hangj distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT zhangj distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp AT zhuh distributionofcopdcomorbiditiesandcreationofacuteexacerbationriskscoreresultsfromscicp |
| _version_ |
1718378050736881664 |
| spelling |
oai:doaj.org-article:8a577d638cf445f1bc01de57d030c0922021-12-02T18:26:43ZDistribution of COPD Comorbidities and Creation of Acute Exacerbation Risk Score: Results from SCICP1178-7031https://doaj.org/article/8a577d638cf445f1bc01de57d030c0922021-07-01T00:00:00Zhttps://www.dovepress.com/distribution-of-copd-comorbidities-and-creation-of-acute-exacerbation--peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Haiyan Ge,1,* Xuanqi Liu,1,* Wenchao Gu,2 Xiumin Feng,3,4 Fengying Zhang,5 Fengfeng Han,6 Yechang Qian,7 Xiaoyan Jin,8 Beilan Gao,9 Li Yu,10 Hong Bao,11 Min Zhou,12 Shengqing Li,13 Zhijun Jie,14 Jian Wang,15 Zhihong Chen,16 Jingqing Hang,5 Jingxi Zhang,3 Huili Zhu1 1Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Respiratory Medicine, Pudong New District People’s Hospital, Shanghai, People’s Republic of China; 3Department of Respiratory and Critical Care Medicine, Changhai Hospital Affiliated to Navy Military Medical University, Shanghai, People’s Republic of China; 4Department of Respiratory and Critical Care Medicine, Changji Branch of First Affiliated Hospital of Xinjiang Medical University, Xinjiang, People’s Republic of China; 5Department of Respiratory Medicine, Putuo District People’s Hospital, Shanghai, People’s Republic of China; 6Department of Respiratory Medicine, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 7Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, People’s Republic of China; 8Department of Respiratory Medicine, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 9Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of China; 10Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 11Department of Respiratory Medicine Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People’s Republic of China; 12Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 13Department of Respiratory and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 14Department of Respiratory Medicine, Shanghai Fifth’s Hospital, Fudan University, Shanghai, People’s Republic of China; 15Department of Respiratory Medicine, Shanghai Ninth’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China; 16Department of Respiratory and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huili Zhu Email zhuhuili001@126.comJingxi Zhang Email jingxizhang2000@126.comBackground: Chronic obstructive pulmonary disease (COPD) often coexists with multiple comorbidities which may have a significant impact on acute exacerbations of patients. At present, what kind of comorbidities affects acute exacerbations and how comorbidities lead to poor prognosis are still controversial. The purpose of our study is to determine the impact of comorbidities on COPD exacerbation and establish an acute exacerbation risk assessment system related to comorbidities.Methods: A total of 742 COPD patients participated in the Shanghai COPD Investigation on Comorbidity Program (SCICP, ChiCTR2000030911). Finally, the baseline information of 415 participants and one-year follow-up data were involved in the analysis. We collected hemogram indices, pulmonary function tests and acute exacerbation of COPD with regular medical follow-up. Q-type cluster analysis was used to determine the clusters of participants. Receiver operating characteristic (ROC) analysis was constructed to assess the ability of indicators in predicting acute exacerbations.Results: Almost 65% of the population we investigated had at least one comorbidity. The distribution and incidence of comorbidities differed between exacerbation group and non-exacerbation group. Three comorbidity clusters were identified: (1) respiratory, metabolic, immune and psychologic disease (non-severe cases); (2) cardiovascular and neoplastic disease (severe cases); (3) less comorbidity. Different sub-phenotypes of COPD patients showed significant distinction in health status. Anxiety (OR=5.936, P=0.001), angina (OR=10.155, P=0.025) and hypertension (OR=3.142, P=0.001) were found to be independent risk factors of exacerbation in a year. The novel risk score containing BODEx and four diseases showed great prognostic value of COPD exacerbation in developing sample.Conclusion: Our study detailed the major interaction between comorbidities and exacerbation in COPD. Noteworthily, a novel risk score using comprehensive index – BODEx – and comorbidity parameters can identify patients at high risk of acute exacerbation.Keywords: chronic obstructive pulmonary disease, exacerbation, comorbidity, risk scoreGe HLiu XGu WFeng XZhang FHan FQian YJin XGao BYu LBao HZhou MLi SJie ZWang JChen ZHang JZhang JZhu HDove Medical Pressarticlechronic obstructive pulmonary disease (copd)exacerbationcomorbidityrisk scorePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3335-3348 (2021) |